Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD

Journal of Hepatology

Volumn 67, Issue 1, 2017, Pages 128-136

  Luukkonen, Panu K ^a,b   Zhou, You ^b,c   Nidhina Haridas, P A ^b   Dwivedi, Om P ^d   Hyötyläinen, Tuulia ^e   Ali, Ashfaq ^f   Juuti, Anne ^a   Leivonen, Marja ^a   Tukiainen, Taru ^d   Ahonen, Linda ^f   Scott, Emma ^g   Palmer, Jeremy M ^g   Arola, Johanna ^a   Orho Melander, Marju ^h   Vikman, Petter ^h   Anstee, Quentin M ^g   Olkkonen, Vesa M ^b   Orešič, Matej ⁱ   Groop, Leif ^d,h   Yki Järvinen, Hannele ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF HELSINKI   (Finland)

^e ÖREBRO UNIVERSITY   (Sweden)

^f STENO DIABETES CENTER   (Denmark)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

^h LUND UNIVERSITY   (Sweden)

ⁱ UNIVERSITY OF TURKU   (Finland)

Author keywords

Arachidonic acid; Cholesterol esters; Fatty acids; Genotype; Hepatocytes; Lipogenesis; Non alcoholic fatty liver disease; Phosphatidylcholines; Transmembrane 6 superfamily member 2; Triglycerides

Indexed keywords

ARACHIDONIC ACID; CHOLESTEROL ESTER; LIPIDOME; LIVER PROTEIN; OLEIC ACID; PALMITIC ACID; PHOSPHATIDYLCHOLINE; POLYUNSATURATED FATTY ACID; TRIACYLGLYCEROL; LIPID; MEMBRANE PROTEIN; TM6SF2 PROTEIN, HUMAN; UNSATURATED FATTY ACID; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; GENETIC VARIABILITY; HETEROZYGOTE; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIPID LIVER LEVEL; LIPOGENESIS; LIVER BIOPSY; LIVER CELL; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; TRANSMEMBRANE 6 SUPERFAMILY MEMBER 2 E167K GENE; TRIACYLGLYCEROL BLOOD LEVEL; BIOSYNTHESIS; GENETICS; LIVER; METABOLISM;

ADULT; FATTY ACIDS, UNSATURATED; FEMALE; HETEROZYGOTE; HUMANS; LIPIDS; LIPOPROTEINS, VLDL; LIVER; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; TRIGLYCERIDES;

EID: 85017448528     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.02.014     Document Type: Article

References (52)

1. Yki-Järvinen, H., Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2 (2014), 901–910.
2. Kozlitina, J., Smagris, E., Stender, S., Nordestgaard, B.G., Zhou, H.H., Tybjærg-Hansen, A., et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 46 (2014), 352–356.
3. Mahdessian, H., Taxiarchis, A., Popov, S., Silveira, A., Franco-Cereceda, A., Hamsten, A., et al. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc Natl Acad Sci USA 111 (2014), 8913–8918.
4. Liu, Y.L., Reeves, H.L., Burt, A.D., Tiniakos, D., McPherson, S., Leathart, J.B., et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun, 5, 2014, 4309.
5. Zhou, Y., Llauradó, G., Orešič, M., Hyötyläinen, T., Orho-Melander, M., Yki-Järvinen, H., Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2. J Hepatol 62 (2015), 657–663.
6. Sookoian, S., Castaño, G.O., Scian, R., Mallardi, P., Fernández Gianotti, T., Burgueño, A.L., et al. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Hepatology 61 (2015), 515–525.
7. Goffredo, M., Caprio, S., Feldstein, A.E., D'Adamo, E., Shaw, M.M., Pierpont, B., et al. Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study. Hepatology 63 (2016), 117–125.
8. Grandone, A., Cozzolino, D., Marzuillo, P., Cirillo, G., Di Sessa, A., Ruggiero, L., et al. TM6SF2 Glu167Lys polymorphism is associated with low levels of LDL-cholesterol and increased liver injury in obese children. Pediatr Obes 11 (2016), 115–119.
9. Eslam, M., Mangia, A., Berg, T., Chan, H.L., Irving, W.L., Dore, G.J., et al. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology, 2016, 10.1002/hep.28475.
10. Mancina, R.M., Sentinelli, F., Incani, M., Bertoccini, L., Russo, C., Romeo, S., et al. Transmembrane-6 superfamily member 2 (TM6SF2) E167K variant increases susceptibility to hepatic steatosis in obese children. Dig Liver Dis 48 (2016), 100–101.
11. Musso, G., Cassader, M., Paschetta, E., Gambino, R., TM6SF2 may drive postprandial lipoprotein cholesterol toxicity away from the vessel walls to the liver in NAFLD. J Hepatol 64 (2016), 979–981.
12. Dongiovanni, P., Petta, S., Maglio, C., Fracanzani, A.L., Pipitone, R., Mozzi, E., et al. TM6SF2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 61 (2015), 506–514.
13. Holmen, O.L., Zhang, H., Fan, Y., Hovelson, D.H., Schmidt, E.M., Zhou, W., et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat Genet 46 (2014), 345–351.
14. Sun, Z., Lazar, M.A., Dissociating fatty liver and diabetes. Trends Endocrinol Metab 24 (2013), 4–12.
15. Cole, L.K., Vance, J.E., Vance, D.E., Phosphatidylcholine biosynthesis and lipoprotein metabolism. Biochim Biophys Acta 1821 (2012), 754–761.
16. Rong, X., Wang, B., Dunham, M.M., Hedde, P.N., Wong, J.S., Gratton, E., et al. Lpcat3-dependent production of arachidonoyl phospholipids is a key determinant of triglyceride secretion. Elife, 25, 2015, 4.
17. Sha, W., da Costa, K.A., Fischer, L.M., Milburn, M.V., Lawton, K.A., Berger, A., et al. Metabolomic profiling can predict which humans will develop liver dysfunction when deprived of dietary choline. FASEB J 24 (2010), 2962–2975.
18. Rinella, M.E., Green, R.M., The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 40 (2004), 47–51.
19. Song, J., da Costa, K.A., Fischer, L.M., Kohlmeier, M., Kwock, L., Wang, S., et al. Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD). FASEB J 19 (2005), 1266–1271.
20. Romeo, S., Cohen, J.C., Hobbs, H.H., No association between polymorphism in PEMT (V175M) and hepatic triglyceride content in the Dallas Heart Study. FASEB J, 20, 2006, 2180.
21. Zeisel, S.H., People with fatty liver are more likely to have the PEMT rs7946 SNP, yet populations with the mutant allele do not have fatty liver. FASEB J 20 (2006), 2181–2182.
22. Dong, H., Wang, J., Li, C., Hirose, A., Nozaki, Y., Takahashi, M., et al. The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population. J Hepatol 46 (2007), 915–920.
23. Spencer, M.D., Hamp, T.J., Reid, R.W., Fischer, L.M., Zeisel, S.H., Fodor, A.A., Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 140 (2011), 976–986.
24. Luukkonen, P.K., Zhou, Y., Sädevirta, S., Leivonen, M., Arola, J., Orešič, M., et al. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J Hepatol 64 (2016), 1167–1175.
25. Alberti, K.G., Zimmet, P.Z., Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998), 539–553.
26. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985), 412–419.
27. DeFronzo, R.A., Matsuda, M., Reduced time points to calculate the composite index. Diabetes Care, 33, 2010, e93.
28. Brunt, E.M., Janney, C.G., Di Bisceglie, A.M., Neuschwander-Tetri, B.A., Bacon, B.R., Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94 (1999), 2467–2474.
29. Hochberg, Y., Benjamini, Y., More powerful procedures for multiple significance testing. Stat Med 9 (1990), 811–818.
30. Cooper, D.E., Young, P.A., Klett, E.L., Coleman, R.A., Physiological Consequences of Compartmentalized Acyl-CoA Metabolism. J Biol Chem 290 (2015), 20023–20031.
31. Pérez-Chacón, G., Astudillo, A.M., Balgoma, D., Balboa, M.A., Balsinde, J., Control of free arachidonic acid levels by phospholipases A2 and lysophospholipid acyltransferases. Biochim Biophys Acta 1791 (2009), 1103–1113.
32. Yao, H., Ye, J., Long chain acyl-CoA synthetase 3-mediated phosphatidylcholine synthesis is required for assembly of very low density lipoproteins in human hepatoma Huh7 cells. J Biol Chem 283 (2008), 849–854.
33. Olofsson, S.O., Borén, J., Apolipoprotein B secretory regulation by degradation. Arterioscler Thromb Vasc Biol 32 (2012), 1334–1338.
34. Smagris, E., Gilyard, S., BasuRay, S., Cohen, J.C., Hobbs, H.H., Inactivation of Tm6sf2, a gene defective in fatty liver disease, impairs lipidation but not secretion of very low density lipoproteins. J Biol Chem 291 (2016), 10659–10676.
35. Noga, A.A., Zhao, Y., Vance, D.E., An unexpected requirement for phosphatidylethanolamine N-methyltransferase in the secretion of very low density lipoproteins. J Biol Chem 277 (2002), 42358–42365.
36. Peter, A., Kovarova, M., Nadalin, S., Cermak, T., Königsrainer, A., Machicao, F., et al. PNPLA3 variant I148M is associated with altered hepatic lipid composition in humans. Diabetologia 57 (2014), 2103–2107.
37. Fisher, E.A., Pan, M., Chen, X., Wu, X., Wang, H., Jamil, H., et al. The triple threat to nascent apolipoprotein B. Evidence for multiple, distinct degradative pathways. J Biol Chem 276 (2001), 27855–27863.
38. Sampath, H., Ntambi, J.M., Polyunsaturated fatty acid regulation of genes of lipid metabolism. Annu Rev Nutr 25 (2005), 317–340.
39. Forman, B.M., Chen, J., Evans, R.M., Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 94 (1997), 4312–4317.
40. Cohn, J.S., Wat, E., Kamili, A., Tandy, S., Dietary phospholipids, hepatic lipid metabolism and cardiovascular disease. Curr Opin Lipidol 19 (2008), 257–262.
41. Wang, Z., Klipfell, E., Bennett, B.J., Koeth, R., Levison, B.S., Dugar, B., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472 (2011), 57–63.
42. George, J., Pera, N., Phung, N., Leclercq, I., Yun Hou, J., Farrell, G., Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol 39 (2003), 756–764.
43. Chen, Q., Galleano, M., Cederbaum, A.I., Cytotoxicity and apoptosis produced by arachidonic acid in Hep G2 cells overexpressing human cytochrome P4502E1. J Biol Chem 272 (1997), 14532–14541.
44. 2 and cyclooxygenase-2. J Biol Chem 275 (2000), 20136–20145.
45. Ishihara, K., Miyazaki, A., Nabe, T., Fushimi, H., Iriyama, N., Kanai, S., et al. Group IVA phospholipase A2 participates in the progression of hepatic fibrosis. FASEB J 26 (2012), 4111–4121.
46. Loomba, R., Quehenberger, O., Armando, A., Dennis, E.A., Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis. J Lipid Res 56 (2015), 185–192.
47. Puri, P., Wiest, M.M., Cheung, O., Mirshahi, F., Sargeant, C., Min, H.K., et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 50 (2009), 1827–1838.
48. Singh, S., Allen, A.M., Wang, Z., Prokop, L.J., Murad, M.H., Loomba, R., Fibrosis progression in nonalcoholic fatty liver vs. nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13 (2015), 643–654, e1–e9.
49. Kabir, Y., Ide, T., Activity of hepatic fatty acid oxidation enzymes in rats fed alpha-linolenic acid. Biochim Biophys Acta 1304 (1996), 105–119.
50. Iacobazzi, V., Infantino, V., Palmieri, F., Transcriptional regulation of the mitochondrial citrate and carnitine/acylcarnitine transporters: two genes involved in fatty acid biosynthesis and β-oxidation. Biology (Basel) 2 (2013), 284–303.
51. Mathur, S.N., Watt, K.R., Field, F.J., Regulation of intestinal NPC1L1 expression by dietary fish oil and docosahexaenoic acid. J Lipid Res 48 (2007), 395–404.
52. Rådmark, O., Werz, O., Steinhilber, D., Samuelsson, B., 5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease. Biochim Biophys Acta 1851 (2015), 331–339.